JP2007519694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519694A5 JP2007519694A5 JP2006550297A JP2006550297A JP2007519694A5 JP 2007519694 A5 JP2007519694 A5 JP 2007519694A5 JP 2006550297 A JP2006550297 A JP 2006550297A JP 2006550297 A JP2006550297 A JP 2006550297A JP 2007519694 A5 JP2007519694 A5 JP 2007519694A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- independently selected
- substituted
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 229910052757 nitrogen Chemical group 0.000 claims 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 239000001301 oxygen Substances 0.000 claims 14
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002429 hydrazines Chemical class 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- JXBGQOJIARFIEK-UHFFFAOYSA-N 3-(3-acetamido-1h-pyrazolo[3,4-b]pyridin-6-yl)-n-cyclopropyl-4-methylbenzamide Chemical compound C=1C=C2C(NC(=O)C)=NNC2=NC=1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 JXBGQOJIARFIEK-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- 229910052731 fluorine Chemical group 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ZUUPPBFBFQLCNJ-UHFFFAOYSA-N n-[6-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]thiophene-2-carboxamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(N=C1NN=2)=CC=C1C=2NC(=O)C1=CC=CS1 ZUUPPBFBFQLCNJ-UHFFFAOYSA-N 0.000 claims 1
- CSYYIPJTYOBZRX-UHFFFAOYSA-N n-cyclopropyl-3-(1-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-5-yl)-5-fluoro-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C(N=CC=12)=CC=1C=NN2S(=O)(=O)C1CC1 CSYYIPJTYOBZRX-UHFFFAOYSA-N 0.000 claims 1
- FUCOMXCSIWZWMP-UHFFFAOYSA-N n-cyclopropyl-3-[1-(2-fluorophenyl)pyrazolo[3,4-c]pyridin-5-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(N=CC=12)=CC=1C=NN2C1=CC=CC=C1F FUCOMXCSIWZWMP-UHFFFAOYSA-N 0.000 claims 1
- IRXOVBVMJTWNEL-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-methylphenyl)pyrazolo[3,4-c]pyridin-5-yl]benzamide Chemical compound CC1=CC=CC(N2C3=CN=C(C=C3C=N2)C=2C(=C(F)C=C(C=2)C(=O)NC2CC2)C)=C1 IRXOVBVMJTWNEL-UHFFFAOYSA-N 0.000 claims 1
- VJOHQXXMKNOOAX-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-5-[3-(4-fluorophenyl)-2h-pyrazolo[3,4-b]pyridin-6-yl]-4-methylbenzamide Chemical compound CC1=C(F)C=C(C(=O)NC2CC2)C=C1C(N=C1NN=2)=CC=C1C=2C1=CC=C(F)C=C1 VJOHQXXMKNOOAX-UHFFFAOYSA-N 0.000 claims 1
- ODOAXTMBIZABMS-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(1-propan-2-ylsulfonylpyrazolo[3,4-c]pyridin-5-yl)benzamide Chemical compound N=1C=C2N(S(=O)(=O)C(C)C)N=CC2=CC=1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 ODOAXTMBIZABMS-UHFFFAOYSA-N 0.000 claims 1
- IVZAVKISSSRRDM-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(1-thiophen-2-ylsulfonylpyrazolo[3,4-c]pyridin-5-yl)benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1C(N=CC=12)=CC=1C=NN2S(=O)(=O)C1=CC=CS1 IVZAVKISSSRRDM-UHFFFAOYSA-N 0.000 claims 1
- JPRFWXHDTCQHRD-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[3-(2-methylpropanoylamino)-1h-pyrazolo[3,4-b]pyridin-6-yl]benzamide Chemical compound C=1C=C2C(NC(=O)C(C)C)=NNC2=NC=1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 JPRFWXHDTCQHRD-UHFFFAOYSA-N 0.000 claims 1
- NHPQXWRHCXVQNT-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[3-(propanoylamino)-1h-pyrazolo[3,4-b]pyridin-6-yl]benzamide Chemical compound C=1C=C2C(NC(=O)CC)=NNC2=NC=1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 NHPQXWRHCXVQNT-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- -1 —CONHR 22 Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402137.4A GB0402137D0 (en) | 2004-01-30 | 2004-01-30 | Novel compounds |
| PCT/GB2005/000274 WO2005073232A1 (en) | 2004-01-30 | 2005-01-27 | P38 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519694A JP2007519694A (ja) | 2007-07-19 |
| JP2007519694A5 true JP2007519694A5 (enExample) | 2008-03-13 |
Family
ID=31971797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550297A Pending JP2007519694A (ja) | 2004-01-30 | 2005-01-27 | Ｐ３８キナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070161673A1 (enExample) |
| EP (1) | EP1709046B1 (enExample) |
| JP (1) | JP2007519694A (enExample) |
| AT (1) | ATE517896T1 (enExample) |
| GB (1) | GB0402137D0 (enExample) |
| WO (1) | WO2005073232A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124941D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ATE375980T1 (de) | 2002-02-12 | 2007-11-15 | Smithkline Beecham Corp | Nicotinamide und deren verwendung als p38 inhibitoren |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402138D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| CA2640049A1 (en) | 2006-01-31 | 2007-08-09 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
| CA2668731A1 (en) | 2006-11-09 | 2008-05-15 | Tobias Gabriel | Kinase inhibitors and methods for using the same |
| WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| WO2008124614A1 (en) | 2007-04-06 | 2008-10-16 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| ES2534573T3 (es) | 2007-04-06 | 2015-04-24 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| FR2985257B1 (fr) * | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| KR102469849B1 (ko) | 2013-04-19 | 2022-11-23 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP3357916A4 (en) * | 2015-09-30 | 2019-06-26 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | benzamide |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| KR20230038807A (ko) | 2016-09-09 | 2023-03-21 | 인사이트 코포레이션 | Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암의 치료를 위한 이의 용도 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| CA3127373A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| HUE059624T2 (hu) | 2018-02-20 | 2022-11-28 | Incyte Corp | N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| PH12022550271A1 (en) | 2019-08-06 | 2023-06-26 | Incyte Corp | Solid forms of an hpk1 inhibitor |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3215903A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR102314026B1 (ko) * | 2021-07-06 | 2021-10-19 | (주)프레이저테라퓨틱스 | p38 MAP 키나아제 억제제로 염증성 질환의 치료 효과를 나타내는 신규 화합물 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000012089A1 (en) * | 1998-08-31 | 2000-03-09 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| GB0124848D0 (en) | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| ATE375980T1 (de) * | 2002-02-12 | 2007-11-15 | Smithkline Beecham Corp | Nicotinamide und deren verwendung als p38 inhibitoren |
| GB0209891D0 (en) * | 2002-04-30 | 2002-06-05 | Glaxo Group Ltd | Novel compounds |
| EP1518323B1 (en) * | 2002-06-19 | 2006-11-02 | R & C Holding ApS | Phase-locked loop with incremental phase detectors and a converter for combining a logical operation with a digital to analog conversion |
| GB0217757D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| WO2004080996A1 (en) * | 2003-03-07 | 2004-09-23 | Eli Lilly And Company | Opioid receptor antagonists |
| GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0402138D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
| GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
-
2004
- 2004-01-30 GB GBGB0402137.4A patent/GB0402137D0/en not_active Ceased
-
2005
- 2005-01-27 US US10/587,989 patent/US20070161673A1/en not_active Abandoned
- 2005-01-27 EP EP05702029A patent/EP1709046B1/en not_active Expired - Lifetime
- 2005-01-27 WO PCT/GB2005/000274 patent/WO2005073232A1/en not_active Ceased
- 2005-01-27 JP JP2006550297A patent/JP2007519694A/ja active Pending
- 2005-01-27 AT AT05702029T patent/ATE517896T1/de not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007519694A5 (enExample) | ||
| JP2005538100A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| CN114846005A (zh) | Shp2抑制剂及其应用 | |
| JP2005509622A5 (enExample) | ||
| RU2018123779A (ru) | Новые соединения | |
| JP2007501831A5 (enExample) | ||
| JP2017512786A5 (enExample) | ||
| JP2005511531A5 (enExample) | ||
| JP2018525375A5 (enExample) | ||
| JP2021502387A5 (enExample) | ||
| JP2005505618A5 (enExample) | ||
| JP2009529047A5 (enExample) | ||
| BR112012030177B1 (pt) | composto ativador da guanilato ciclase solúvel, e, composição farmacêutica | |
| ME02906B (me) | Derivati pirazolopirolidina i njihova upotreba u liječenju bolesti | |
| BR112017016193B1 (pt) | Derivados de 4h-pirrolo[3,2-c]piridin-4-ona | |
| HRP20170712T1 (hr) | Novi spojevi selektivnih antagonista nk-3 receptora, farmaceutski pripravak i postupci za uporabu kod poremećaja uzrokovanih nk-3 receptorima | |
| JP2005508967A5 (enExample) | ||
| ZA200508158B (en) | Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | |
| JP2004506736A5 (enExample) | ||
| JP2014516074A5 (enExample) | ||
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2017508766A5 (enExample) | ||
| JP2007519695A5 (enExample) | ||
| RU2014107000A (ru) | Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств |